Den samlede frekvens for disse alvorlige uønskede reaktioner var 0, 1% blandt modtagere af RotaTeq og 0, 2% blandt modtagere af placebo.
The overall frequency of these serious adverse reactions was 0.1% among recipients of RotaTeq and 0.2% among placebo recipients.